Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Issue published August 16, 2004 Previous issue | Next issue

  • Volume 114, Issue 4
Go to section:
  • In this issue
  • Book Review
  • News
  • Review
  • Commentaries
  • Research Articles
  • Errata
  • Corrigendum
In this issue
In This Issue
/articles/view/120005
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):447-447. https://doi.org/10.1172/JCI120005.
View: Text | PDF

In This Issue

  • Text
  • PDF
Abstract

Authors

×
Book Review
Is it in your genes? The influence of genes on common disorders and diseases that affect you and your family
Fuki M. Hisama
Fuki M. Hisama
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):449-449. https://doi.org/10.1172/JCI22762.
View: Text | PDF

Is it in your genes? The influence of genes on common disorders and diseases that affect you and your family

  • Text
  • PDF
Abstract

Authors

Fuki M. Hisama

×
News
High-tech coal mine canary
Laurie Goodman
Laurie Goodman
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):448-448. https://doi.org/10.1172/JCI22768.
View: Text | PDF

High-tech coal mine canary

  • Text
  • PDF
Abstract

Authors

Laurie Goodman

×
Review
Progress on new vaccine strategies against chronic viral infections
Jay A. Berzofsky, … , Masaki Terabe, Igor M. Belyakov
Jay A. Berzofsky, … , Masaki Terabe, Igor M. Belyakov
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/JCI22674.
View: Text | PDF

Progress on new vaccine strategies against chronic viral infections

  • Text
  • PDF
Abstract

Among the most cost-effective strategies for preventing viral infections, vaccines have proven effective primarily against viruses causing acute, self-limited infections. For these it has been sufficient for the vaccine to mimic the natural virus. However, viruses causing chronic infection do not elicit an immune response sufficient to clear the infection and, as a result, vaccines for these viruses must elicit more effective responses — quantitative and qualitative — than does the natural virus. Here we examine the immunologic and virologic basis for vaccines against three such viruses, HIV, hepatitis C virus, and human papillomavirus, and review progress in clinical trials to date. We also explore novel strategies for increasing the immunogenicity and efficacy of vaccines.

Authors

Jay A. Berzofsky, Jeffrey D. Ahlers, John Janik, John Morris, SangKon Oh, Masaki Terabe, Igor M. Belyakov

×
Commentaries
RANKing c-Jun in osteoclast development
Steven L. Teitelbaum
Steven L. Teitelbaum
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):463-465. https://doi.org/10.1172/JCI22644.
View: Text | PDF

RANKing c-Jun in osteoclast development

  • Text
  • PDF
Abstract

Pathological bone loss always reflects enhanced net osteoclastic activity. Recognition and binding of the receptor activator of NF-κB (RANK) by RANK ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades induced by this reaction therefore contain potential anti-osteoporosis therapeutic targets. A study reported in this issue of the JCI documents that a pivotal component of RANKL/RANK-mediated osteoclast recruitment involves sequential induction of the transcription factors c-Jun and nuclear factor of activated T cells 2 .

Authors

Steven L. Teitelbaum

×

AMP-activated protein kinase: the guardian of cardiac energy status
D. Grahame Hardie
D. Grahame Hardie
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):465-468. https://doi.org/10.1172/JCI22683.
View: Text | PDF

AMP-activated protein kinase: the guardian of cardiac energy status

  • Text
  • PDF
Abstract

Several years ago it was proposed that the AMP-activated protein kinase cascade might protect cells against stresses that deplete cellular ATP. Young et al. have now directly tested this by studying the effects of ischemia and reperfusion in perfused hearts from mice expressing a dominant-negative mutant that suppresses the kinase activity in cardiac muscle. Compared with control hearts, the mutant hearts showed clear evidence for increased necrotic damage and increased apoptosis. These findings may have implications for the treatment of ischemic heart disease.

Authors

D. Grahame Hardie

×

Immune recognition of self in immunity against cancer
Alan N. Houghton, José A. Guevara-Patiño
Alan N. Houghton, José A. Guevara-Patiño
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):468-471. https://doi.org/10.1172/JCI22685.
View: Text | PDF

Immune recognition of self in immunity against cancer

  • Text
  • PDF
Abstract

Most antigens expressed by human cancer cells and recognized by host T cells and antibodies are nonmutated self antigens — molecules also expressed on the surface of normal cells. These self antigens are ineffective at triggering immune responses against cancer cells, which provides one explanation for the difficulties in trying to immunize against human cancer. A new study describes how tumors can avoid recognition by the immune system and how enhancing the affinity of the interaction between a self antigen and the MHC-I molecule may lead to cancer immunity.

Authors

Alan N. Houghton, José A. Guevara-Patiño

×

The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis
Gary S. Firestein
Gary S. Firestein
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):471-474. https://doi.org/10.1172/JCI22651.
View: Text | PDF | Erratum

The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis

  • Text
  • PDF
Abstract

The etiology of autoimmunity in humans remains poorly defined, and animal models provide a unique opportunity to study potential autoimmune mechanisms. A novel model of autoimmune inflammatory arthritis results from a point mutation in the ζ-associated–protein of 70 kDa (ZAP-70), which causes abnormal thymic T cell selection and survival of autoreactive clones. Although the resulting clinical and pathologic abnormalities are clearly T cell–dependent, macrophage and fibroblast cytokines such as IL-1 and TNF-α are required for full expression of the disease. The studies of Hata et al. raise the intriguing possibility that traditional proinflammatory cytokine networks represent common effector mechanisms in inflammatory joint diseases such as rheumatoid arthritis. Hence, effective therapeutic interventions can target either unique etiologic pathways related to adaptive immune responses or shared terminal mechanisms.

Authors

Gary S. Firestein

×
Research Articles
Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation
Fumiyo Ikeda, … , Anjana Rao, Toshiyuki Yoneda
Fumiyo Ikeda, … , Anjana Rao, Toshiyuki Yoneda
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):475-484. https://doi.org/10.1172/JCI19657.
View: Text | PDF

Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation

  • Text
  • PDF
Abstract

Receptor activator of NF-κB ligand (RANKL) plays an essential role in osteoclast formation and bone resorption. Although genetic and biochemical studies indicate that RANKL regulates osteoclast differentiation by activating receptor activator of NF-κB and associated signaling molecules, the molecular mechanisms of RANKL-regulated osteoclast differentiation have not yet been fully established. We investigated the role of the transcription factor c-Jun, which is activated by RANKL, in osteoclastogenesis using transgenic mice expressing dominant-negative c-Jun specifically in the osteoclast lineage. We found that the transgenic mice manifested severe osteopetrosis due to impaired osteoclastogenesis. Blockade of c-Jun signaling also markedly inhibited soluble RANKL-induced osteoclast differentiation in vitro. Overexpression of nuclear factor of activated T cells 1 (NFAT1) (NFATc2/NFATp) or NFAT2 (NFATc1/NFATc) promoted differentiation of osteoclast precursor cells into tartrate-resistant acid phosphatase–positive (TRAP–positive) multinucleated osteoclast-like cells even in the absence of RANKL. Overexpression of NFAT1 also markedly transactivated the TRAP gene promoter. These osteoclastogenic activities of NFAT were abrogated by overexpression of dominant-negative c-Jun. Importantly, osteoclast differentiation and induction of NFAT2 expression by NFAT1 overexpression or soluble RANKL treatment were profoundly diminished in spleen cells of the transgenic mice. Collectively, these results indicate that c-Jun signaling in cooperation with NFAT is crucial for RANKL-regulated osteoclast differentiation.

Authors

Fumiyo Ikeda, Riko Nishimura, Takuma Matsubara, Sakae Tanaka, Jun-ichiro Inoue, Sakamuri V. Reddy, Kenji Hata, Kenji Yamashita, Toru Hiraga, Toshiyuki Watanabe, Toshio Kukita, Katsuji Yoshioka, Anjana Rao, Toshiyuki Yoneda

×

Temporal perturbations in sonic hedgehog signaling elicit the spectrum of holoprosencephaly phenotypes
Dwight Cordero, … , Minal Tapadia, Jill A. Helms
Dwight Cordero, … , Minal Tapadia, Jill A. Helms
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):485-494. https://doi.org/10.1172/JCI19596.
View: Text | PDF

Temporal perturbations in sonic hedgehog signaling elicit the spectrum of holoprosencephaly phenotypes

  • Text
  • PDF
Abstract

One of the most perplexing questions in clinical genetics is why patients with identical gene mutations oftentimes exhibit radically different clinical features. This inconsistency between genotype and phenotype is illustrated in the malformation spectrum of holoprosencephaly (HPE). Family members carrying identical mutations in sonic hedgehog (SHH) can exhibit a variety of facial features ranging from cyclopia to subtle midline asymmetries. Such intrafamilial variability may arise from environmental factors acting in conjunction with gene mutations that collectively reduce SHH activity below a critical threshold. We undertook a series of experiments to test the hypothesis that modifying the activity of the SHH signaling pathway at discrete periods of embryonic development could account for the phenotypic spectrum of HPE. Exposing avian embryos to cyclopamine during critical periods of craniofacial development recreated a continuum of HPE-related defects. The craniofacial malformations included hypotelorism, midfacial hypoplasia, and facial clefting and were not the result of excessive crest cell apoptosis. Rather, they resulted from molecular reprogramming of an organizing center whose activity controls outgrowth and patterning of the mid and upper face. Collectively, these data reveal one mechanism by which the variable expressivity of a disorder such as HPE can be produced through temporal disruption of a single molecular pathway.

Authors

Dwight Cordero, Ralph Marcucio, Diane Hu, William Gaffield, Minal Tapadia, Jill A. Helms

×

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury
Raymond R. Russell III, … , Morris J. Birnbaum, Lawrence H. Young
Raymond R. Russell III, … , Morris J. Birnbaum, Lawrence H. Young
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):495-503. https://doi.org/10.1172/JCI19297.
View: Text | PDF

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

  • Text
  • PDF
Abstract

AMP-activated protein kinase (AMPK) is an important regulator of diverse cellular pathways in the setting of energetic stress. Whether AMPK plays a critical role in the metabolic and functional responses to myocardial ischemia and reperfusion remains uncertain. We examined the cardiac consequences of long-term inhibition of AMPK activity in transgenic mice expressing a kinase dead (KD) form of the enzyme. The KD mice had normal fractional shortening and no heart failure, cardiac hypertrophy, or fibrosis, although the in vivo left ventricular (LV) dP/dt was lower than that in WT hearts. During low-flow ischemia and postischemic reperfusion in vitro, KD hearts failed to augment glucose uptake and glycolysis, although glucose transporter content and insulin-stimulated glucose uptake were normal. KD hearts also failed to increase fatty acid oxidation during reperfusion. Furthermore, KD hearts demonstrated significantly impaired recovery of LV contractile function during postischemic reperfusion that was associated with a lower ATP content and increased injury compared with WT hearts. Caspase-3 activity and TUNEL-staining were increased in KD hearts after ischemia and reperfusion. Thus, AMPK is responsible for activation of glucose uptake and glycolysis during low-flow ischemia and plays an important protective role in limiting damage and apoptotic activity associated with ischemia and reperfusion in the heart.

Authors

Raymond R. Russell III, Ji Li, David L. Coven, Marc Pypaert, Christoph Zechner, Monica Palmeri, Frank J. Giordano, James Mu, Morris J. Birnbaum, Lawrence H. Young

×

Collecting duct–specific knockout of endothelin-1 causes hypertension and sodium retention
Dowhan Ahn, … , Raoul D. Nelson, Donald E. Kohan
Dowhan Ahn, … , Raoul D. Nelson, Donald E. Kohan
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):504-511. https://doi.org/10.1172/JCI21064.
View: Text | PDF

Collecting duct–specific knockout of endothelin-1 causes hypertension and sodium retention

  • Text
  • PDF
Abstract

In vitro studies suggest that collecting duct–derived (CD-derived) endothelin-1 (ET-1) can regulate renal Na reabsorption; however, the physiologic role of CD-derived ET-1 is unknown. Consequently, the physiologic effect of selective disruption of the ET-1 gene in the CD of mice was determined. Mice heterozygous for aquaporin2 promoter Cre recombinase and homozygous for loxP-flanked exon 2 of the ET-1 gene (called CD-specific KO of ET-1 [CD ET-1 KO] mice) were generated. These animals had no CD ET-1 mRNA and had reduced urinary ET-1 excretion. CD ET-1 KO mice on a normal Na diet were hypertensive, while body weight, Na excretion, urinary aldosterone excretion, and plasma renin activity were unchanged. CD ET-1 KO mice on a high-Na diet had worsened hypertension, reduced urinary Na excretion, and excessive weight gain, but showed no differences between aldosterone excretion and plasma renin activity. Amiloride or furosemide reduced BP in CD ET-1 KO mice on a normal or high-Na diet and prevented excessive Na retention in salt-loaded CD ET-1 KO mice. These studies indicate that CD-derived ET-1 is an important physiologic regulator of renal Na excretion and systemic BP.

Authors

Dowhan Ahn, Yuqiang Ge, Peter K. Stricklett, Pritmohinder Gill, Deborah Taylor, Alisa K. Hughes, Masashi Yanagisawa, Lance Miller, Raoul D. Nelson, Donald E. Kohan

×

Foxa2 regulates multiple pathways of insulin secretion
Kristen A. Lantz, … , Franz M. Matschinsky, Klaus H. Kaestner
Kristen A. Lantz, … , Franz M. Matschinsky, Klaus H. Kaestner
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):512-520. https://doi.org/10.1172/JCI21149.
View: Text | PDF

Foxa2 regulates multiple pathways of insulin secretion

  • Text
  • PDF
Abstract

The regulation of insulin secretion by pancreatic β cells is perturbed in several diseases, including adult-onset (type 2) diabetes and persistent hyperinsulinemic hypoglycemia of infancy (PHHI). The first mouse model for PHHI has a conditional deletion of the gene encoding the winged-helix transcription factor Foxa2 (Forkhead box a2, formerly Hepatocyte nuclear factor 3β) in pancreatic β cells. Using isolated islets, we found that Foxa2 deficiency resulted in excessive insulin release in response to amino acids and complete loss of glucose-stimulated insulin secretion. Most PHHI cases are associated with mutations in SUR1 (Sulfonylurea receptor 1) or KIR6.2 (Inward rectifier K+ channel member 6.2), which encode the subunits of the ATP-sensitive K+ channel, and RNA in situ hybridization of mutant mouse islets revealed that expression of both genes is Foxa2 dependent. We utilized expression profiling to identify additional targets of Foxa2. Strikingly, one of these genes, Hadhsc, encodes short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase, deficiency of which has been shown to cause PHHI in humans. Hadhsc is a direct target of Foxa2, as demonstrated by cotransfection as well as in vivo chromatin immunoprecipitation experiments using isolated islets. Thus, we have established Foxa2 as an essential activator of genes that function in multiple pathways governing insulin secretion.

Authors

Kristen A. Lantz, Marko Z. Vatamaniuk, John E. Brestelli, Joshua R. Friedman, Franz M. Matschinsky, Klaus H. Kaestner

×

Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis
David Q.-H. Wang, … , Alan S. Kopin, Martin C. Carey
David Q.-H. Wang, … , Alan S. Kopin, Martin C. Carey
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):521-528. https://doi.org/10.1172/JCI16801.
View: Text | PDF

Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis

  • Text
  • PDF
Abstract

Cholecystokinin (CCK) modulates contractility of the gallbladder, the sphincter of Oddi, and the stomach. These effects are mediated through activation of gastrointestinal smooth muscle as well as enteric neuron CCK-1 receptors (CCK-1Rs). To investigate the potential physiological and pathophysiological functions linked to CCK-1R–mediated signaling, we compared male WT and CCK-1R–deficient mice (129/SvEv). After 12 weeks on either a standard mouse chow or a lithogenic diet (containing 1% cholesterol, 0.5% cholic acid, and 15% dairy fat), small-intestinal transit time, intestinal cholesterol absorption, biliary cholesterol secretion, and cholesterol gallstone prevalence were compared in knockout versus WT animals. Analysis of mice on either the chow or the lithogenic diet revealed that CCK-1R–/– animals had larger gallbladder volumes (predisposing to bile stasis), significant retardation of small-intestinal transit times (resulting in increased cholesterol absorption), and increased biliary cholesterol secretion rates. The elevation in bile cholesterol, coupled with a tendency toward gallbladder stasis (due to the absence of CCK-induced contraction), facilitates nucleation, growth, and agglomeration of cholesterol monohydrate crystals; this sequence of events in turn results in a significantly higher prevalence of cholesterol gallstones in the CCK-1R–null mice.

Authors

David Q.-H. Wang, Frank Schmitz, Alan S. Kopin, Martin C. Carey

×

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease
Lemin Zheng, … , Michael Kinter, Stanley L. Hazen
Lemin Zheng, … , Michael Kinter, Stanley L. Hazen
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):529-541. https://doi.org/10.1172/JCI21109.
View: Text | PDF

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

  • Text
  • PDF
Abstract

In recent studies we demonstrated that systemic levels of protein-bound nitrotyrosine (NO2Tyr) and myeloperoxidase (MPO), a protein that catalyzes generation of nitrating oxidants, serve as independent predictors of atherosclerotic risk, burden, and incident cardiac events. We now show both that apolipoprotein A-I (apoA-I), the primary protein constituent of HDL, is a selective target for MPO-catalyzed nitration and chlorination in vivo and that MPO-catalyzed oxidation of HDL and apoA-I results in selective inhibition in ABCA1-dependent cholesterol efflux from macrophages. Dramatic selective enrichment in NO2Tyr and chlorotyrosine (ClTyr) content within apoA-I recovered from serum and human atherosclerotic lesions is noted, and analysis of serum from sequential subjects demonstrates that the NO2Tyr and ClTyr contents of apoA-I are markedly higher in individuals with cardiovascular disease (CVD). Analysis of circulating HDL further reveals that higher NO2Tyr and ClTyr contents of the lipoprotein are each significantly associated with diminished ABCA1-dependent cholesterol efflux capacity of the lipoprotein. MPO as a likely mechanism for oxidative modification of apoA-I in vivo is apparently facilitated by MPO binding to apoA-I, as revealed by cross-immunoprecipitation studies in plasma, recovery of MPO within HDL-like particles isolated from human atheroma, and identification of a probable contact site between the apoA-I moiety of HDL and MPO. To our knowledge, the present results provide the first direct evidence for apoA-I as a selective target for MPO-catalyzed oxidative modification in human atheroma. They also suggest a potential mechanism for MPO-dependent generation of a proatherogenic dysfunctional form of HDL in vivo.

Authors

Lemin Zheng, Benedicta Nukuna, Marie-Luise Brennan, Mingjiang Sun, Marlene Goormastic, Megan Settle, Dave Schmitt, Xiaoming Fu, Leonor Thomson, Paul L. Fox, Harry Ischiropoulos, Jonathan D. Smith, Michael Kinter, Stanley L. Hazen

×

Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo
Tihui Fu, … , Kui Shin Voo, Rong-Fu Wang
Tihui Fu, … , Kui Shin Voo, Rong-Fu Wang
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):542-550. https://doi.org/10.1172/JCI22053.
View: Text | PDF

Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo

  • Text
  • PDF
Abstract

CD4+ T cells play important roles in orchestrating host immune responses against cancer and infectious diseases. Although EBV-encoded nuclear antigen 1–specific (EBNA1-specific) CD4+ T cells have been implicated in controlling the growth of EBV-associated tumors such as Burkitt lymphoma (BL) in vitro, direct evidence for their in vivo function remains elusive due to the lack of an appropriate experimental BL model. Here, we describe the development of a mouse EBNA1-expressing BL tumor model and the identification of 2 novel MHC H-2I-Ab–restricted T cell epitopes derived from EBNA1. Using our murine BL tumor model and the relevant peptides, we show that vaccination of mice with EBNA1 peptide–loaded DCs can elicit CD4+ T cell responses. These EBNA1-specific CD4+ T cells recognized peptide-pulsed targets as well as EBNA1-expressing tumor cells and were necessary and sufficient for suppressing tumor growth in vivo. By contrast, EBNA1 peptide–reactive CD8+ T cells failed to recognize tumor cells and did not contribute to protective immunity. These studies represent what we believe to be the first demonstration that EBNA1-specific CD4+ T cells can suppress tumor growth in vivo, which suggests that CD4+ T cells play an important role in generating protective immunity against EBV-associated cancer.

Authors

Tihui Fu, Kui Shin Voo, Rong-Fu Wang

×

Poor immunogenicity of a self/tumor antigen derives from peptide–MHC-I instability and is independent of tolerance
Zhiya Yu, … , Brian M. Baker, Nicholas P. Restifo
Zhiya Yu, … , Brian M. Baker, Nicholas P. Restifo
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):551-559. https://doi.org/10.1172/JCI21695.
View: Text | PDF

Poor immunogenicity of a self/tumor antigen derives from peptide–MHC-I instability and is independent of tolerance

  • Text
  • PDF
Abstract

Understanding the mechanisms underlying the poor immunogenicity of human self/tumor antigens is challenging because of experimental limitations in humans. Here, we developed a human-mouse chimeric model that allows us to investigate the roles of the frequency and self-reactivity of antigen-specific T cells in determination of the immunogenicity of an epitope (amino acids 209–217) derived from a human melanoma antigen, gp100. In these transgenic mice, CD8+ T cells express the variable regions of a human T cell receptor (hTCR) specific for an HLA-A*0201–restricted gp100209–217. Immunization of hTCR-transgenic mice with gp100209–217 peptide elicited minimal T cell responses, even in mice in which the epitope was knocked out. Conversely, a modified epitope, gp100209–217(2M), was significantly more immunogenic. Both biological and physical assays revealed a fast rate of dissociation of the native peptide from the HLA-A*0201 molecule and a considerably slower rate of dissociation of the modified peptide. In vivo, the time allowed for dissociation of peptide-MHC complexes on APCs prior to their exposure to T cells significantly affected the induction of immune responses. These findings indicate that the poor immunogenicity of some self/tumor antigens is due to the instability of the peptide-MHC complex rather than to the continual deletion or tolerization of self-reactive T cells.

Authors

Zhiya Yu, Marc R. Theoret, Christopher E. Touloukian, Deborah R. Surman, Scott C. Garman, Lionel Feigenbaum, Tiffany K. Baxter, Brian M. Baker, Nicholas P. Restifo

×

Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer
Jennifer D. Wu, … , Kathy Haugk, Stephen R. Plymate
Jennifer D. Wu, … , Kathy Haugk, Stephen R. Plymate
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):560-568. https://doi.org/10.1172/JCI22206.
View: Text | PDF

Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer

  • Text
  • PDF
Abstract

The MHC class I chain–related molecules (MICs) have previously been shown to be induced on most epithelial tumor cells. Engagement of MIC by the activating immune receptor NKG2D triggers NK cells and augments antigen-specific CTL anti-tumor immunity. The MIC-NKG2D system was proposed to participate in epithelial tumor immune surveillance. Paradoxically, studies suggest that tumors may evade MIC-NKG2D–mediated immunity by MIC shedding–induced impairment of effector cell function. Here we demonstrate the first evidence to our knowledge of a significant correlation of MIC shedding and deficiency in NK cell function with the grade of disease in prostate cancer. MIC is widely expressed in prostate carcinoma. The presence of surface target MIC, however, is counteracted by shedding. A significant increase in serum levels of soluble MIC (sMIC) and deficiency in NK cell function was shown in patients with advanced cancer. Finally, the deficiency in NK cell function can be overcome by treatment with IL-2 or IL-15 in vitro. Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D–mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.

Authors

Jennifer D. Wu, Lily M. Higgins, Alexander Steinle, David Cosman, Kathy Haugk, Stephen R. Plymate

×

NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
Margit A. Huber, … , Hartmut Beug, Thomas Wirth
Margit A. Huber, … , Hartmut Beug, Thomas Wirth
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):569-581. https://doi.org/10.1172/JCI21358.
View: Text | PDF

NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression

  • Text
  • PDF
Abstract

The transcription factor NF-κB is activated in a range of human cancers and is thought to promote tumorigenesis, mainly due to its ability to protect transformed cells from apoptosis. To investigate the role of NF-κB in epithelial plasticity and metastasis, we utilized a well-characterized in vitro/in vivo model of mammary carcinogenesis that depends on the collaboration of the Ha-Ras oncoprotein and TGF-β. We show here that the IKK-2/IκBα/NF-κB pathway is required for the induction and maintenance of epithelial-mesenchymal transition (EMT). Inhibition of NF-κB signaling prevented EMT in Ras-transformed epithelial cells, while activation of this pathway promoted the transition to a mesenchymal phenotype even in the absence of TGF-β. Furthermore, inhibition of NF-κB activity in mesenchymal cells caused a reversal of EMT, suggesting that NF-κB is essential for both the induction and maintenance of EMT. In line with the importance of EMT for invasion, blocking of NF-κB activity abrogated the metastatic potential of mammary epithelial cells in a mouse model system. Collectively, these data provide evidence of an essential role for NF-κB during distinct steps of breast cancer progression and suggest that the cooperation of Ras- and TGF-β–dependent signaling pathways in late-stage tumorigenesis depends critically on NF-κB activity.

Authors

Margit A. Huber, Ninel Azoitei, Bernd Baumann, Stefan Grünert, Andreas Sommer, Hubert Pehamberger, Norbert Kraut, Hartmut Beug, Thomas Wirth

×

Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell–mediated spontaneous autoimmune arthritis in mice
Hiroshi Hata, … , Takashi Nakamura, Shimon Sakaguchi
Hiroshi Hata, … , Takashi Nakamura, Shimon Sakaguchi
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):582-588. https://doi.org/10.1172/JCI21795.
View: Text | PDF

Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell–mediated spontaneous autoimmune arthritis in mice

  • Text
  • PDF
Abstract

Cytokines play key roles in spontaneous CD4+ T cell–mediated chronic autoimmune arthritis in SKG mice, a new model of rheumatoid arthritis. Genetic deficiency in IL-6 completely suppressed the development of arthritis in SKG mice, irrespective of the persistence of circulating rheumatoid factor. Either IL-1 or TNF-α deficiency retarded the onset of arthritis and substantially reduced its incidence and severity. IL-10 deficiency, on the other hand, exacerbated disease, whereas IL-4 or IFN-γ deficiency did not alter the disease course. Synovial fluid of arthritic SKG mice contained high amounts of IL-6, TNF-α, and IL-1, in accord with active transcription of these cytokine genes in the afflicted joints. Notably, immunohistochemistry revealed that distinct subsets of synovial cells produced different cytokines in the inflamed synovium: the superficial synovial lining cells mainly produced IL-1 and TNF-α, whereas scattered subsynovial cells produced IL-6. Thus, IL-6, IL-1, TNF-α, and IL-10 play distinct roles in the development of SKG arthritis; arthritogenic CD4+ T cells are not required to skew to either Th1 or Th2; and the appearance of rheumatoid factor is independent of joint inflammation. The results also indicate that targeting not only each cytokine but also each cell population secreting distinct cytokines could be an effective treatment of rheumatoid arthritis.

Authors

Hiroshi Hata, Noriko Sakaguchi, Hiroyuki Yoshitomi, Yoichiroh Iwakura, Kenji Sekikawa, Yoshiaki Azuma, Chieko Kanai, Eiko Moriizumi, Takashi Nomura, Takashi Nakamura, Shimon Sakaguchi

×

Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes
Peter Achenbach, … , Anette-G. Ziegler, Ezio Bonifacio
Peter Achenbach, … , Anette-G. Ziegler, Ezio Bonifacio
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):589-597. https://doi.org/10.1172/JCI21307.
View: Text | PDF

Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes

  • Text
  • PDF
Abstract

Children at risk for type 1 diabetes can develop early insulin autoantibodies (IAAs). Many, but not all, of these children subsequently develop multiple islet autoantibodies and diabetes. To determine whether disease progression is reflected by autoantibody maturity, IAA affinity was measured by competitive radiobinding assay in first and subsequent IAA-positive samples from children followed from birth in the BABYDIAB cohort. IAA affinity in first positive samples ranged from less than 106 l/mol to more than 1011 l/mol. High affinity was associated with HLA DRB1*04, young age of IAA appearance, and subsequent progression to multiple islet autoantibodies or type 1 diabetes. IAA affinity in multiple antibody–positive children was on average 100-fold higher than in children who remained single IAA positive or became autoantibody negative. All high-affinity IAAs required conservation of human insulin A chain residues 8–13 and were reactive with proinsulin. In contrast, most lower-affinity IAAs were dependent on COOH-terminal B chain residues and did not bind proinsulin. These data are consistent with the concept that type 1 diabetes is associated with sustained early exposure to (pro)insulin in the context of HLA DR4 and show that high-affinity proinsulin-reactive IAAs identify children with the highest diabetes risk.

Authors

Peter Achenbach, Kerstin Koczwara, Annette Knopff, Heike Naserke, Anette-G. Ziegler, Ezio Bonifacio

×
Errata
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model
Rolf Postina, … , Fred van Leuven, Falk Fahrenholz
Rolf Postina, … , Fred van Leuven, Falk Fahrenholz
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):598-598. https://doi.org/10.1172/JCI20864E1.
View: Text | PDF | Amended Article

A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model

  • Text
  • PDF
Abstract

Authors

Rolf Postina, Anja Schroeder, Ilse Dewachter, Juergen Bohl, Ulrich Schmitt, Elzbieta Kojiro, Claudia Prinzen, Kristina Endres, Christoph Hiemke, Manfred Blessing, Pascaline Flamez, Antoine Dequenne, Emile Godaux, Fred van Leuven, Falk Fahrenholz

×

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
David H. Munn, … , Pandelakis A. Koni, Andrew L. Mellor
David H. Munn, … , Pandelakis A. Koni, Andrew L. Mellor
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):599-599. https://doi.org/10.1172/JCI21583E1.
View: Text | PDF | Amended Article

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

  • Text
  • PDF
Abstract

Authors

David H. Munn, Madhav D. Sharma, Deyan Hou, Babak Baban, Jeffrey R. Lee, Scott J. Antonia, Jane L. Messina, Phillip Chandler, Pandelakis A. Koni, Andrew L. Mellor

×
Corrigendum
Acute renal failure: definitions, diagnosis, pathogenesis, and therapy
Robert W. Schrier, … , Brian Poole, Amit Mitra
Robert W. Schrier, … , Brian Poole, Amit Mitra
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):598-598. https://doi.org/10.1172/JCI22353C1.
View: Text | PDF | Amended Article

Acute renal failure: definitions, diagnosis, pathogenesis, and therapy

  • Text
  • PDF
Abstract

Authors

Robert W. Schrier, Wei Wang, Brian Poole, Amit Mitra

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts